Health Canada Approves Phase 1 Trial for Moderna's Bundibugyo Ebola Vaccine

Health Canada has granted authorization for Moderna to commence a Phase 1 clinical trial for its mRNA-1469 vaccine candidate, targeting the Bundibugyo Ebola virus. This marks Canada as the second nation to approve such a trial, which will evaluate the vaccine's safety, optimal dosage, and potential side effects in healthy volunteers. There is currently no approved vaccine or treatment available for this specific type of Ebola, which is linked to an ongoing outbreak in the Democratic Republic of the Congo.